Chemotherapy in Combination With Erlotinib, or Sequential Chemotherapy for Erlotinib for Treatment, EGFR - TKI Resistance of EGFR Mutations in Patients With NSCLC Randomized Controlled Phase II Clinical Study
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2018
Price : $35 *
At a glance
- Drugs Erlotinib (Primary) ; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017, according to ClinicalTrials.gov record.
- 22 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017, according to ClinicalTrials.gov record.
- 19 Feb 2014 New trial record